A comparison of quantitative computerized and human panel coronary endpoint measures: Implications for the design of angiographic trials

Controlled Clinical Trials

Volumn 18, Issue 2, 1997, Pages 168-179

  Mack, Wendy J ^a,b   Azen, Stanley P ^a   Dunn, Meleana ^a   Hodis, Howard N ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b Department of Preventive Medicine ^*  (United States)

Author keywords

clinical trial; coronary angiography; endpoint

Indexed keywords

LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN;

ANGIOGRAPHY; ARTICLE; ATHEROSCLEROSIS; CLINICAL TRIAL; COMPUTER; CONTROLLED CLINICAL TRIAL; DATA ANALYSIS; DATA BASE; DOUBLE BLIND PROCEDURE; HUMAN; RANDOMIZED CONTROLLED TRIAL;

ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; COMPUTERS; CORONARY ANGIOGRAPHY; CORONARY DISEASE; DATA INTERPRETATION, STATISTICAL; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LOVASTATIN; MALE; OBSERVER VARIATION; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN;

EID: 0030975078     PISSN: 01972456     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-2456(96)00181-X     Document Type: Article

References (24)

1. Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987;257:3233-3240.
2. Levy RI, Brensike JF, Epstein SE et al. The influence of changes in lipid values induced by cholestyramine and diet on progression of coronary artery disease: results of NHLBI Type II Coronary Intervention Study. Circulation 1984;69:325-337.
3. Buchwald H, Varco RL, Matts JP et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med 1990;323:946-955.
4. Blankenhorn DH, Azen SP, Kramsch DM et al. Results and comparative clinical significance of the Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med 1993;119:969-976.
5. Brown BG, Alber JJ, Fisher LD et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990;323:1289-1298.
6. Artzenius AC, Kromhout D, Barth JD et al. Diet, lipoproteins, and the progression of coronary atherosclerosis: the Leiden Intervention Trial. N Engl J Med 1985; 312:805-811.
7. Lichtlen PR, Hugenholtz PG, Rafflenbeul W, Hecker H, Jost S, Deckers JW. Retardation of angiographic progression of coronary artery disease by nifedipine. Results of the International Nifedipine Trial on Antiatherosclerotic Therapy (INTACT). Lancet 1990;335:1109-1113.
8. Ornish DM, Brown SE, Scherwitz LW et al. Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial. Lancet 1990;336:129-133.
9. Waters D, Lesperance J, Francetich M et al. A controlled clinical trial to assess the effect of a calcium channel blocker on the progression of coronary atherosclerosis. Circulation 1990;82:1940-1953.
10. Kane JP, Malloy JM, Ports TA, Phillips NR, Diehl JC, Havel RJ. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 1990;264:3007-3012.
11. Blankenhorn DH, Selzer RH, Mack WJ et al. Evaluation of colestipol/niacin therapy with computer-derived coronary end point measures: a comparison of different measures of treatment effect. Circulation 1992;86:1701-1709.
12. Watts GF, Lewis B, Brunt JNH et al. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St. Thomas' Atherosclerosis Regression Study (STARS). Lancet 1992;339:563-569.
13. Waters D, Higginson L, Gladstone P et al. Effects of monotherapy with an HmG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography: Canadian Coronary Atherosclerosis Intervention Trial. Circulation 1994;89:959-968.
14. MAAS Investigators: Effect of simvastatin on coronary atheroma: the Multicenter Anti-Atheroma Study (MAAS). Lancet 1994;344:633-638.
15. Brown BG, Bolson EL, Dodge HT. Arteriographic assessment of coronary atherosclerosis. Review of current methods, their limitations, and clinical applications. Arteriosclerosis 1982;2:2-15.
16. Brensike JF, Levy RI, Kelsey SF et al. Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study. Circulation 1984;69:313-324.
17. Cashin-Hemphill L, Mack W, Pogoda J, Sanmarco M, Azen SP, Blankenhorn DH. Beneficial effects of colestipol-niacin on coronary atherosclerosis. A four year followup. JAMA 1990;264:3013-3017.
18. Azen SP, Mack WJ, Cashin-Hemphill L et al. Progression of coronary artery disease predicts clinical coronary events: long-term follow-up from the Cholesterol Lowering Atherosclerosis Study. Circulation 1996;93:34-41.
19. Cashin-Hemphill L, Kramsch DM, Azen SP et al. The Monitored Atherosclerosis Regression Study (MARS). Design, methods, and baseline results. On-Line Journal of Current Clinical Trials. 1992; Document 26.
20. McCullagh P, Neider JA. Generalized linear models. London: Chapman and Hall, 1983, pp. 149-155.
21. Azen SP, Cashin-Hemphill L, Pogoda J et al. An evaluation of human panelists in assessing coronary atherosclerosis. Arteriosclerosis Thromb 1991;11:385-394.
22. Mack WJ, Selzer RH, Pogoda J et al. Comparison of computer and human coronary angiographic endpoint measures for controlled therapy trials. Arteriosclerosis Thromb 1992;12:348-356.
23. Blankenhorn DH, Selzer RH, Mack WJ et al. Evaluation of colestipol/niacin therapy with computer-derived coronary end point measures: a comparison of different measures of treatment effect. Circulation 1992;86:1701-1709.
24. Buchwald H, Matts J, Fitch LL et al. Changes in sequential coronary arteriograms and subsequent coronary events. JAMA 1992;268:1429-1433.